Provention Bio

Provention Bio, Inc. is a biopharmaceutical company dedicated to blocking and preventing immune-mediated diseases. The company's main product, PRV-3279, is currently in the research and development stage: one for the treatment of systemic lupus erythematosus, which is in Phase 1 clinical trials in the United States; the other for preventing or reducing the immunogenicity of gene therapy, which is in preclinical studies in the United States.